{"id":"dual-antiplatelet-agent-duration","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding (major and minor)"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1","effect":"Intracranial hemorrhage"},{"rate":"5-10","effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dual antiplatelet agent therapy typically combines aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide synergistic antiplatelet effects. This combination is more effective at preventing stent thrombosis and recurrent ischemic events than monotherapy, though it increases bleeding risk. The duration of therapy is tailored based on clinical context, balancing ischemic and bleeding risks.","oneSentence":"Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:05.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with percutaneous coronary intervention"},{"name":"Stable coronary artery disease with stent placement"},{"name":"Secondary prevention of myocardial infarction and stent thrombosis"}]},"trialDetails":[{"nctId":"NCT04957719","phase":"PHASE3","title":"Selatogrel Outcome Study in Suspected Acute Myocardial Infarction","status":"ENROLLING_BY_INVITATION","sponsor":"Viatris Innovation GmbH","startDate":"2021-08-14","conditions":"Acute Myocardial Infarction","enrollment":14000},{"nctId":"NCT05225961","phase":"PHASE4","title":"ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-05-01","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT05707442","phase":"PHASE3","title":"Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-16","conditions":"Idiopathic Intracranial Hypotension, Venous Sinus Stenosis","enrollment":74},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT04708587","phase":"NA","title":"Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2021-03-23","conditions":"Chronic Kidney Diseases","enrollment":900},{"nctId":"NCT05257824","phase":"PHASE4","title":"Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-06-23","conditions":"Aneurysm Cerebral, Endovascular Procedures","enrollment":528},{"nctId":"NCT05631769","phase":"PHASE4","title":"HOST - DAPT Duration According the Bleeding Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-07-24","conditions":"Coronary Artery Disease, Acute Myocardial Infarction, Stable Angina","enrollment":4900},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":"Stroke, Transient Ischemic Attack (TIA)","enrollment":200},{"nctId":"NCT06718179","phase":"PHASE4","title":"Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-16","conditions":"Acute Coronary Syndrome","enrollment":3150},{"nctId":"NCT04418479","phase":"PHASE4","title":"SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3","status":"COMPLETED","sponsor":"Joo-Yong Hahn","startDate":"2020-08-10","conditions":"Coronary Artery Disease","enrollment":5506},{"nctId":"NCT06683300","phase":"","title":"Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11","conditions":"Vertebral Artery Stenosis","enrollment":520},{"nctId":"NCT02619760","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":3045},{"nctId":"NCT04609111","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2021-01-29","conditions":"Acute Coronary Syndrome","enrollment":6002},{"nctId":"NCT03462498","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2018-04-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":3008},{"nctId":"NCT04135989","phase":"PHASE4","title":"Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2020-01-01","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome","enrollment":2106},{"nctId":"NCT02099617","phase":"NA","title":"Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.","status":"COMPLETED","sponsor":"Ceric Sàrl","startDate":"2014-05","conditions":"Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome","enrollment":1200},{"nctId":"NCT06175377","phase":"NA","title":"Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-03-30","conditions":"Chronic Total Occlusion","enrollment":660},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT05936606","phase":"NA","title":"Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-08-16","conditions":"Coronary Artery Disease","enrollment":3434},{"nctId":"NCT04135677","phase":"PHASE4","title":"Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-11-11","conditions":"Left Atrial Appendage Thrombosis, Thrombi, Stroke","enrollment":826},{"nctId":"NCT05487560","phase":"","title":"An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-04-18","conditions":"Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months","enrollment":4133},{"nctId":"NCT03198741","phase":"PHASE4","title":"Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2017-07-13","conditions":"Gastrointestinal Injury, Ischemic Heart Disease","enrollment":783},{"nctId":"NCT03023020","phase":"NA","title":"Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2017-04-04","conditions":"High Bleeding Risk, Coronary Artery Disease, PCI","enrollment":4579},{"nctId":"NCT03355742","phase":"NA","title":"XIENCE 28 Global Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2018-02-09","conditions":"Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic","enrollment":963},{"nctId":"NCT02594501","phase":"NA","title":"Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy","status":"UNKNOWN","sponsor":"CeloNova BioSciences, Inc.","startDate":"2016-02-05","conditions":"Angina, Stable, Angina, Unstable, Anticoagulants","enrollment":996},{"nctId":"NCT00963781","phase":"PHASE4","title":"Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)","status":"COMPLETED","sponsor":"Scripps Health","startDate":"2009-08","conditions":"Coronary Artery Disease, Coronary Thrombosis","enrollment":219},{"nctId":"NCT04590131","phase":"NA","title":"Efficacy and Safety Comparison of the Endovascular and the Hybrid Methods for the Treatment of Prolonged Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee, TASC II, Type D","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2020-11-01","conditions":"Atherosclerosis, Ischemia Limb, Superficial Femoral Artery Occlusion","enrollment":100},{"nctId":"NCT03732066","phase":"NA","title":"Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2019-01-14","conditions":"Coronary Disease","enrollment":760},{"nctId":"NCT04129008","phase":"PHASE4","title":"GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-10-17","conditions":"Coronary Artery Disease, Gastroesophageal Reflux Disease","enrollment":88},{"nctId":"NCT03038009","phase":"PHASE4","title":"Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft","status":"WITHDRAWN","sponsor":"Ruijin Hospital","startDate":"2018-10","conditions":"Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract, Proton Pump Inhibitor","enrollment":""},{"nctId":"NCT03522038","phase":"","title":"Functional Assessment-guided Angioplasty in Patients With Coronary Chronic Total Occlusion","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-08-01","conditions":"Coronary Occlusion, Angioplasty, Balloon, Coronary","enrollment":300},{"nctId":"NCT03338335","phase":"","title":"Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2017-03-01","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy","enrollment":16000},{"nctId":"NCT02227368","phase":"PHASE2","title":"Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-10-20","conditions":"Peripheral Artery Disease (PAD)","enrollment":40},{"nctId":"NCT02618265","phase":"NA","title":"Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-01","conditions":"Stroke","enrollment":400},{"nctId":"NCT02391883","phase":"","title":"Hip-Fracture Surgery on Patients in Clopidogrel Therapy","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2011-01","conditions":"Hip Fracture","enrollment":356},{"nctId":"NCT02303717","phase":"NA","title":"Xience Versus Synergy in Left Main PCI","status":"UNKNOWN","sponsor":"NHS National Waiting Times Centre Board","startDate":"2014-12","conditions":"Coronary Artery Disease","enrollment":818},{"nctId":"NCT00822536","phase":"PHASE4","title":"Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-01","conditions":"Coronary Artery Disease, Stent Thrombosis, Myocardial Ischemia","enrollment":1798},{"nctId":"NCT01186146","phase":"PHASE4","title":"Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2010-08","conditions":"Coronary Artery Disease","enrollment":5000},{"nctId":"NCT01543932","phase":"PHASE3","title":"High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2012-07","conditions":"Coronary Artery Disease","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dual antiplatelet agent duration","genericName":"Dual antiplatelet agent duration","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events. Used for Acute coronary syndrome with percutaneous coronary intervention, Stable coronary artery disease with stent placement, Secondary prevention of myocardial infarction and stent thrombosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}